Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZETA-STAT is a **small molecule inhibitor** specifically targeting the zeta isoform of protein kinase C (PKC-ζ). It is chemically known as 1,3,6-naphthalenetrisulfonic acid. ZETA-STAT demonstrates selective inhibition of PKC-ζ with an IC50 of 5 μM, exhibiting minimal inhibition (13% at 20 μM) against other PKC isoforms such as PKC-I. The compound is primarily used in biochemical research to probe the role of PKC-ζ in various cellular signaling pathways, including those relevant to cell differentiation, proliferation, and survival[9]. No therapeutic indication or clinical development in humans has been reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zeta-stat.